美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Corgi IP Licensing & Royalties ETF

26.44

0.0000

成交量：1

成交额：26.09

市值：145.45万

市盈率：- -

高：26.44

开：26.44

低：26.44

收：26.44

52周最高：27.92

52周最低：25.36

股本：5.50万

流通股本：5.50万

量比：0.25

换手率：0.00%

股息：- -

股息率：- -

净资产收益率：-378.67%

总资产收益率：-70.26%

市净率：0.13

市盈率(LYR):- -

数据加载中...

总览公司新闻公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻

帕拉丁宣布口服MC4R激动剂PL7737在肥胖动物模型中取得积极临床前疗效数据

华尔街洞察

Palatin公布口服MC4R激动剂PL7737在肥胖动物模型中积极临床前功效数据

华尔街洞察

Palatin口服肥胖新药PL7737临床前数据亮眼，计划2026年启动I期试验

华尔街洞察

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/PTNT"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTNT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTNT\",,,,,undefined,":{"symbol":"PTNT","market":"US","secType":"STK","nameCN":"Corgi IP Licensing & Royalties ETF","latestPrice":26.4449,"timestamp":1782310058451,"preClose":26.4449,"halted":0,"volume":1,"delay":0,"changeRate":0,"floatShares":55000,"shares":55000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"06-24 10:30:23 EDT","open":26.4449,"high":26.4449,"low":26.4449,"amount":26.085,"amplitude":0,"askPrice":26.19,"askSize":1500,"bidPrice":26.15,"bidSize":1500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1782331200000},"marketStatusCode":2,"adr":0,"listingDate":1778040000000,"exchange":"CBOE","adjPreClose":26.4449,"nav":26.75,"aum":1471250,"bidAskSpread":0,"volumeRatio":0.249744,"impliedVol":0.5825,"impliedVolPercentile":0.2727},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTNT\",,,,,undefined,":{"symbol":"PTNT","floatShares":55000,"roa":"-70.26%","roe":"-378.67%","lyrEps":0,"volumeRatio":0.249744,"shares":55000,"dividePrice":0,"high":26.4449,"amplitude":0,"preClose":26.4449,"low":26.4449,"week52Low":25.36,"pbRate":"0.13","psRate":"0.16","week52High":27.924,"institutionHeld":0.1111,"latestPrice":26.4449,"eps":0,"divideRate":0,"volume":1,"delay":0,"ttmEps":0,"open":26.4449,"prevYearClose":25.59,"prevWeekClose":26.4449,"prevMonthClose":27.153,"prevQuarterClose":25.59,"fiveDayClose":26.4449,"twentyDayClose":25.4599},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTNT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTNT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTNT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTNT\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1115580369","title":"帕拉丁宣布口服MC4R激动剂PL7737在肥胖动物模型中取得积极临床前疗效数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1115580369","media":"华尔街洞察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115580369?lang=zh_cn&edition=fundamental","pubTime":"2025-07-15 20:43","pubTimestamp":1752583435,"startTime":"0","endTime":"0","summary":"帕拉丁科技公司公布了其口服MC4R激动剂PL7737在肥胖动物模型中的积极临床前疗效数据。研究显示，PL7737与替西帕肽联用产生附加减肥效果，口服给药后在短短四天内即实现快速体重减轻。公司计划于2025年第四季度提交PL7737的新药研究申请（IND），为后续开发铺路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159628542","title":"Palatin公布口服MC4R激动剂PL7737在肥胖动物模型中积极临床前功效数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1159628542","media":"华尔街洞察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159628542?lang=zh_cn&edition=fundamental","pubTime":"2025-07-15 20:43","pubTimestamp":1752583426,"startTime":"0","endTime":"0","summary":"Palatin Technologies, Inc.今日宣布，其口服MC4R激动剂PL7737在肥胖动物模型中的临床前研究显示积极功效。研究结果表明，PL7737与tirzepatide联用可产生显著的加性减肥效果。效果惊人！口服PL7737在短短4天内即实现快速体重减轻。公司计划于2025年第四季度提交PL7737的新药临床试验申请（IND）。这一进展突显了该药物在肥胖治疗领域的潜力，为未来临床试验奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105523922","title":"Palatin口服肥胖新药PL7737临床前数据亮眼，计划2026年启动I期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1105523922","media":"华尔街洞察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105523922?lang=zh_cn&edition=fundamental","pubTime":"2025-07-15 19:33","pubTimestamp":1752579200,"startTime":"0","endTime":"0","summary":"生物医药企业Palatin Technologies近日公布其口服MC4R激动剂PL7737在肥胖症动物模型中取得突破性临床前数据。更值得注意的是，当PL7737与替西帕肽联用时，两者产生协同减重效应，减重幅度超越单一用药效果。根据研发规划，Palatin将于2025年第四季度向美国食品药品监督管理局提交PL7737的新药临床试验申请，预计2026年上半年公布首个人体试验数据。值得关注的是，PL7737已获得美国FDA授予的孤儿药资格认定，适应症为瘦素受体缺乏症相关肥胖。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PTNT\",params:#limit:6,delay:false,,,undefined,":[]}}